Sponsorship Statement:
This continuing education activity is jointly sponsored by 
and 
Support Statement:
This activity is supported by an educational grant from 
Target Audience: This program is designed for oncologists, hematologists/oncologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer.
Learning Objectives: At the conclusion of this activity participants should be able to:
- Explain current immunotherapy strategies being evaluated in non-small cell lung cancer (NSCLC).
- Evaluate key efficacy and safety data from clinical trials of protein-, peptide-, and cellular-based vaccines.
- Identify effective vaccine strategies for early- and advanced-stage NSCLC based on patient and disease characteristics.
Course Chair:
Roy S. Herbst, MD, PhD
Chief of Medical Oncology
Yale Cancer Center
Section of Medical Oncology
New Haven, Connecticut
Faculty:
Charles A. Butts, MD
Medical Oncologist
Associate Professor of Oncology
Cross Cancer Institute
University of Alberta
Edmonton, Alberta
Ronald B. Natale, MD
Director
Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
John Nemunaitis, MD
Executive Medical Director
Mary Crowley Cancer Research Center
Dallas, Texas
External Reviewer:
Paul Blum, MD
Accreditation:
This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HemOnc Today® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 18, 2011 to November 17, 2012.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch and listen to the presentations, complete the posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the
relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Roy S. Herbst MD, PhD
Grant Support/Research Funding: Genentech, Amgen, BMS, AstraZeneca, Novartis, OSI, Oncothyreion, Geron, Sanofi Aventis, Pfizer, Imclone.
Paid Consultant/Honoraria: Genentech, Argennix Inc, Allos Therapeutics, Boehringer Ingelheim, OSI. Scientific Advisory Boards: Biotheria, Genetics Squred, MedTrust, N of One, SynDev Rx, Targeted Molecular Diagnostics, DiaTech.
Charles A. Butts, MD
Consulting Fees: GlaxoSmithKline, Merck-Serono.
Ronald B. Natale, MD
Contracted Research: Eli Lilly, Novartis, Medimmune.
John Nemunaitis, MD
Receipt of Intellectual property rights/Patent holder: Gradalis.
External Reviewer reports the following relationship(s):
Paul Blum, MD
No relevant financial relationships to disclose.
HemOnc Today® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HemOnc Today® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HemOnc Today® . Neither Vindico Medical Education, HemOnc Today® , nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.